UMass Chan clinical trial reveals antisense oligonucleotide safely suppresses mutant ALS gene in pilot human study
WORCESTER, Mass. – Using a short, synthetic chain of chemically modified nucleotides engineered in the RNA Therapeutics Institute at UMass Chan